Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta University, Georgia
J Clin Psychiatry. 2020 Nov 3;81(6):NU19047BR4C. doi: 10.4088/JCP.NU19047BR4C.
Clinicians now have 2 effective and well-tolerated vesicular monoamine transporter 2 (VMAT2) inhibitors-valbenazine and deutetrabenazine-for the treatment of patients with tardive dyskinesia (TD), a severe and potentially irreversible side effect associated with dopamine receptor blocking agents. Clinicians should use measurement-based care, eg, the Abnormal Involuntary Movement Scale with activation maneuvers, to assess and document TD symptoms and treatment progress. Each follow-up visit should be personalized with questions related to patients' functioning and level of distress regarding their specific TD symptoms. Family members, if available, can provide information on symptom changes and assistance with medication adherence. With continued treatment and measurement-based care, patients can experience improvement in their TD symptoms.
目前，临床医生有两种有效的、耐受良好的囊泡单胺转运体 2（VMAT2）抑制剂——valbenazine 和 deutetrabenazine，用于治疗迟发性运动障碍（TD）患者。TD 是一种与多巴胺受体阻滞剂相关的严重且潜在不可逆的副作用。临床医生应使用基于测量的护理方法，例如带有激活操作的异常不自主运动量表，来评估和记录 TD 症状和治疗进展。每次随访应根据患者的功能和对特定 TD 症状的困扰程度进行个性化处理，并提出相关问题。如果有家属在场，他们可以提供有关症状变化的信息，并帮助患者坚持服药。通过持续治疗和基于测量的护理，患者的 TD 症状可以得到改善。
